International Journal of New Chemistry
ISC, DOAJ, CAS, Google Scholar......

A New Survey on SOS1 Inhibitors as Promising Therapeutic Molecules

Document Type : Research Paper

Authors

Mohammad Mahboubi-Rabbani
Pardis Kondori
Hoda Hashemifard

Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

https://doi.org/10.22034/ijnc.2024.715696
Abstract
SOS1 (Son of Sevenless 1) is a guanine nucleotide exchange factor that plays a crucial role in the activation of the RAS signaling pathway, making it a significant target for therapeutic intervention in various cancers. Recent developments in the field of medicinal chemistry have led to the identification and optimization of SOS1 inhibitors, which exhibit diverse chemical structures that impact their biological activity. This abstract discusses the chemical scaffolds of SOS1 inhibitors, highlighting key structural features that contribute to their potency and selectivity. Structure-activity relationship (SAR) studies reveal that modifications in functional groups, ring systems, and stereochemistry can significantly influence the binding affinity to the SOS1 protein and downstream effects on RAS activation. By analyzing various classes of SOS1 inhibitors, including small molecules and peptidomimetics, this work elucidates the interplay between chemical structure and biological function. The findings underscore the importance of rational design in the development of effective SOS1 inhibitors, paving the way for novel therapeutic strategies against RAS-driven malignancies.

Keywords

SOS1
Enzyme inhibitors
Docking
Structure-activity relationship
Subjects
[1] I. Ali et al., Current Drug Therapy., 92-113 (2019).
[2] S. M. Nabavi et al., Food Chemistry., 339-347 (2015).
[3] M. F. Ahmad et al., Journal of Herbal Medicine., 100404 (2021).
[4] S. Nasir Abbas Bukhari, M. Jasamai, and I. Jantan, Mini Reviews in Medicinal Chemistry., 1394-1403 (2012).
[5] A. Rani, A. Anand, K. Kumar, and V. Kumar, Expert Opinion on Drug Discovery., 249-288 (2019).
[6] D. I. Batovska and I. T. Todorova, Current Clinical Pharmacology., 1-29 (2010).
[7] B. Zhou and C. Xing, Medicinal Chemistry., 388 (2015).
[8] D. Kar Mahapatra, V. Asati, and S. K. Bharti, Expert Opinion on Therapeutic Patents., 385-406 (2019).
[9] S. B. Ötvös et al., Molecules., 318 (2016).
[10] D. K. Mahapatra, S. K. Bharti, and V. Asati, European Journal of Medicinal Chemistry., 496-524 (2015).
[11] K. K. Irwin, N. Renzette, T. F. Kowalik, and J. D. Jensen, Virus Evolution., vew014 (2016).
[12] T.-L. Lee, Asian J. WTO & Int'l Health L & Pol'y., 27 (2020).
[13] M. Pal, G. Berhanu, C. Desalegn, and V. Kandi, Cureus., (2020).
[14] E. K. Stokes, MMWR. Morbidity and Mortality Weekly Report., (2020).
[15] S. Baron, M. Fons, and T. Albrecht, Medical Microbiology., (1996).
[16] E. De Clercq and G. Li, Clinical Microbiology Reviews., 695-747 (2016).
[17] P. Ravanfar, A. Satyaprakash, R. Creed, and N. Mendoza, Dermatologic Therapy., 110-128 (2009).
[18] E. De Clercq, Nature Reviews Drug Discovery., 13-25 (2002).
[19] Z. Lou, Y. Sun, and Z. Rao, Trends in Pharmacological Sciences., 86-102 (2014).
[20] K. Malbari et al., Acta Virol., 179-190 (2018).
[21] S. Jo, H. Kim, S. Kim, D. H. Shin, and M. S. Kim, Chemical Biology & Drug Design., 2023-2030 (2019).
[22] V. Patil et al., Medicinal Chemistry., 150-161 (2019).
[23] A. Hameed et al., Bioorganic Chemistry., 175-182 (2016).
[24] M. Mathaiyan, A. Suresh, and R. Balamurugan, Bioinformation., 279 (2018).
[25] J.-P. Monserrat et al., Bioorganic & Medicinal Chemistry Letters., 6195-6197 (2011).
[26] H. Sharma et al., Bioorganic & Medicinal Chemistry., 2030-2045 (2011).
[27] J. Deng et al., Bioorganic & Medicinal Chemistry., 3785-3792 (2006).
[28] J. Deng et al., Bioorganic & Medicinal Chemistry., 4985-5002 (2007).
International Journal of New Chemistry
Volume 11, Issue 4
Winter 2024
Pages 457-468

Home

Reviewers